Chronic Lymphocytic Leukemia Coverage from Every Angle

Published Medical Literature

Are Immunoglobulin Alterations Prognostic of Outcomes in CLL?
NOTCH1 Mutation in CLL and Response to Ibrutinib
COVID-19 and CLL: Rare Case of Pseudohypoxemia
Ibrutinib Therapy for CLL: Real-World Outcomes From Denmark
Hematopoietic Cell Transplantation for TP53-Mutant or Deleted CLL: Long-Term Outcomes
How Comorbidities May Affect Response to Idelalisib-Based Therapy in CLL
Fixed-Duration Combination Regimen Under Study in CLL
Swedish Study Centers on Cardiovascular Disease in Patients With CLL
Serious Inpatient Bacterial Infections and Survival in Patients With CLL
Case of Tumor-Lysis Syndrome After Combination CLL Therapy
COVID‐19 and CLL: Case Report of Viral Co-infection With Parainfluenza
Real-World Data From Czech Study Group on CD20 Antibody Plus Chemotherapy for CLL
Can Camptothecin-11 Analog Improve Response to Fludarabine in CLL?
Subcutaneous Versus Intravenous Rituximab in CLL: Canadian Experience
IGHV Mutations and the Relationship Between Translocation and Time to Treatment in CLL
Biomarker May Aid in the Stratification of Prognostic Groups for CLL
Does UGT2B17 Alter Treatment Response in CLL?
Pleural Empyema Caused by Rare Infection in a Patient With CLL
Atypical Case of Chronic Lymphocytic Leukemia Treated With R-CHOP
Novel Prognostic Model May Predict Outcomes in Early-Stage CLL
COVID-19 and CLL: Barcelona Hospital Experience
CAR T-Cell Therapy for CLL: Comparing Doses and Outcomes
Case Reports: Iron Overload Without Blood Transfusion in CLL
Review of Appropriate Therapies for Patients With CLL After Venetoclax Discontinuation
Dosing Schedules May Affect Outcomes With Acalabrutinib in CLL
Long-Term Data Support Ibrutinib Monotherapy in Patients With CLL/SLL
Chemoimmunotherapy vs Chemotherapy in CLL: 5-Year Follow-up of Complement 1 Trial
Do Dose Interruptions Affect Survival in Ibrutinib-Treated Patients With CLL?
Combination Regimens Targeting Multiple Kinases: Fruitful Avenue of CLL Research?
Use of Duvelisib After Ofatumumab in Resistant CLL/SLL
Treatment Potential of CAR-Transduced Natural Killer Cells in CLL
Meta-analysis Supports Maintenance Therapy for Reducing CLL Progression
CLL-Stereotyped Immunoglobulin Gene Rearrangements in Normal B-Cell Subsets
Sequential Combination Therapy for Chronic Lymphocytic Leukemia
Moxetumomab Pasudotox Therapy Under Study in Resistant Hairy Cell Leukemia
Early-Phase Study of Acalabrutinib Plus Obinutuzumab in CLL
Potential Effect of Antigen Drive on T-Cell Repertoire in CLL
Minimal Residual Disease and Chemotherapy-Free Regimens in CLL: Surrogate Prognostic Marker?
CNS Aspergillosis After Ibrutinib Treatment for CLL: A Case Study
Case Study: Multifungal Infection in a Patient Treated With Ibrutinib for CLL
Early Discontinuation of First-Line Ibrutinib in CLL in the Real-World Setting
Response Rates to Venetoclax Plus Ibrutinib in High-Risk CLL
Could a Novel Endogenous Ligand Be a Potential Target for CLL Treatment?
Study Finds MicroRNA Targets p53 Gene in Epstein-Barr Virus–Associated CLL
Combination of Rituximab and High-Dose Methylprednisolone for High-Risk Patients With CLL
Expanding Use of Cyclophosphamide After Transplantation in CLL
Tracking Clonal Evolution in Patients With Stable and Progressive CLL
Exploring the Synergy Between Idelalisib and Bendamustine in Treating CLL
Use of Ibrutinib in CLL: Update 5 Years After Approval
Venetoclax Therapy for Elderly Patients With Resistant CLL
Next-Generation Sequencing and Minimal Residual Disease in Patients With CLL
Five-Year Outcomes With Front-Line Ibrutinib in CLL
CLARITY Trial Update of Ibrutinib Plus Venetoclax in Resistant CLL
Does the Mode of Disease Progression Affect Outcomes in CLL?
Putting Clonal Evolution to Practical Use in Chronic Lymphocytic Leukemia
Survival Outcomes in CLL: Ibrutinib/Rituximab Versus Standard Chemoimmunotherapy
Phase III Trial Shows Venetoclax/Obinutuzumab Active in First-Line Treatment of CLL
Early Results With Cirmtuzumab/Ibrutinib Therapy for CLL
Immunotherapy Under Study in Resistant CLL: ZUMA-8 Trial
Phase II Trial of Acalabrutinib in Ibrutinib-Intolerant Patients With CLL
Gait Speed and Grip Strength: Predictors of Outcome in Hematologic Malignancies?
Newer Treatment Regimen for High-Risk and Older Patients With CLL
Considerations in Selecting Treatment in Resistant CLL
Addition of Ibrutinib to Initial Treatment for Younger Patients With CLL
Long-Term Study Confirms Benefit of Idelalisib in Relapsed CLL
Do Ibrutinib Dose Modifications Affect Long-Term Benefits in CLL?
Natural Killer Cell Function Activated by CD19-Targeted Molecule in CLL
Suboptimal Dosing of Ibrutinib in Patients With CLL
Minimal Residual Disease Status and Long-Term Survival in CLL
Potential of Nitrostyrene Compounds in CLL
Do Risks Outweigh Benefits for Use of Idelalisib Plus Ofatumumab in CLL?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.